Clinical Performance of Nano Plus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease
Safety and Efficacy of Polymer-free Sirolimus-eluting Coronary Stents in Patients With Coronary Artery Disease.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Chen Wang, PhD
- Phone Number: 15802929290
Study Contact Backup
- Name: Jin-Zan Cai, MSc
- Phone Number: 15720800327
Study Locations
-
-
Shanxi
-
Xi'an, Shanxi, China
- Recruiting
- Xijing Hospital
-
Contact:
- Chen Wang
- Phone Number: 15802929290
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18-85 years old, male or non-pregnancy female;
- Patients with coronary artery disease who match the indication of stent implantation;
- Patients who can understand the nature of the study, agree to participate and accept clinical follow-up;
Exclusion Criteria:
- Patients who can not tolerate the material or medication in this study;
- Pregnancy or lactation women
- Patients who had participated in another investigational drug or device trial that has not completed the primary endpoint;
- Patients are, in the opinion of the investigator, unable to comply with the requirements of the study protocol
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
NANO Plus SES
All patients will be treated with NANO plus sirolimus-eluting stent.
Patients will be prescribed with clopidogrel and aspirin before the index procedure.
The lesions will be predilted if necessary before stent implantation.
There are no specific limitations on coronary lesions according the study criteria.
|
The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
target lesion failure (TLF)
Time Frame: 12 months
|
cardiac death, target vessel related myocardial infarction and/or clinically driven target lesion revascularization
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Target lesion failure
Time Frame: 1、6、12、24、36、48、60 months
|
a composite endpoint of cardiac death, target lesion related myocardial infarction, and/or target lesion revascularization
|
1、6、12、24、36、48、60 months
|
|
Patient oriented composite endpoint
Time Frame: 1、6、12、24、36、48、60 months
|
a composite endpoint of all cause death, all myocardial infarction and all revascularization
|
1、6、12、24、36、48、60 months
|
|
all cause death
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
cardiac death
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
Myocardial infarction
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
Stent thrombosis
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
Target lesion revascularization
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
Target vessel revascularization
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
target lesion failure
Time Frame: 1、6、24、36、48、60 months
|
cardiac death, target vessel related myocardial infarction and/or clinically driven target lesion revascularization
|
1、6、24、36、48、60 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Yao-Jun Zhang, PhD, Nanjing First Hospital, Nanjing Medical University
- Principal Investigator: Lin Tao, PhD, Xijing Hospital
- Principal Investigator: Yue Li, PhD, The First Clinical Hospital affiliated to Harbin Medical University
- Principal Investigator: Zhiqi Sun, PhD, Daqing oilfield central hospital
Publications and helpful links
General Publications
- Suwannasom P, Onuma Y, Benit E, Gach O, von Birgelen C, Hofma SH, Sotomi Y, Bo X, Zhang YJ, Gao R, Garcia-Garcia HM, Wykrzykowska JJ, de Winter RJ, Serruys PW. Evaluation of vascular healing of polymer-free sirolimus-eluting stents in native coronary artery stenosis: a serial follow-up at three and six months with optical coherence tomography imaging. EuroIntervention. 2016 Aug 5;12(5):e574-83. doi: 10.4244/EIJV12I5A97.
- Zhang Y, Chen F, Muramatsu T, Xu B, Li Z, Ge J, He Q, Yang Z, Li S, Wang L, Wang H, He B, Li K, Qi G, Li T, Zeng H, Peng J, Jiang T, Zeng Q, Zhu J, Fu G, Bourantas CV, Serruys PW, Huo Y. Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial. Chin Med J (Engl). 2014;127(11):2153-8.
- Dai Y, Wang R, Chen F, Zhang Y, Liu Y, Huang H, Yang P, Zhang R, Zheng B, Gao C, Chen Y, Tao L. Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry. BMC Cardiovasc Disord. 2021 Nov 12;21(1):537. doi: 10.1186/s12872-021-02356-0.
- Liu Y, Zhang Y, Li Y, Qi T, Pan D, Wang H, Liu C, Ma D, Fang Z, Zhang R, Mou F, Tao L; NANO All-Comers Registry Investigators. One-year clinical results of the NANO registry: A multicenter, prospective all-comers registry study in patients receiving implantation of a polymer-free sirolimus-eluting stent. Catheter Cardiovasc Interv. 2020 Feb;95 Suppl 1:658-664. doi: 10.1002/ccd.28734. Epub 2020 Jan 21.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NANOxijing001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.